stockrow
Monday 9 November 2026
Export AYTU’s income statement to Excel — free account
Aytu BioPharma, Inc.
AYTUHealthcare Drug Manufacturers Specialty & Generic
Aytu BioPharma, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $57.6 million, down 13.3% from fiscal 2025.
- Revenue
- +6.42%
- EPS
- +100.0%
- Free cash flow
- +57.7%
- Total debt
- −21.9%
Quarter to June 2026, against a year earlier
1.83
0.02
+1.10%
Follow AYTU
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 3 | 3 | 3 |
| (49.33%) | (108.72%) | (97.24%) | (52.55%) | ||
| (10.86%) | (20.52%) | (28.87%) | (12.44%) | ||
ROIC |
(29.63%) | (106.20%) | (31.33%) | (19.99%) | |
Return on Tangible Assets |
(83.70%) | (218.98%) | (438.80%) | (190.36%) | |
Average Days of Receivables |
190.39 | 180.19 | 157.93 | 144.42 | |
Free Cash Flow per Share |
(0.14) | (0.06) | 0.15 | 0.26 | |
Free Cash Flow |
(1.36) | (0.55) | 1.58 | 3.24 | |
Capital Expenditures |
— | 0.04 | (0.10) | (0.05) | |
| Other line items | |||||
Cash ROIC |
(1.65%) | (0.85%) | 1.88% | 4.12% | |
Accounts Receivable Turnover |
2.26 | 2.22 | 1.88 | 2.13 | |
Accounts Payable Turnover |
1.60 | 1.60 | 1.58 | 1.90 | |
Inventory Turnover |
1.89 | 2.10 | 2.15 | 2.27 | |
Average Days of Payables |
218.00 | 250.58 | 241.93 | 198.47 | |
Days of Inventory on Hand |
178.40 | 152.12 | 136.58 | 120.66 | |
Tax Rate |
0.00 | 0.00 | 0.01 | 0.03 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 1.59% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
59.26% | 62.41% | 71.90% | 74.07% | |
Share Based Compensation of Revenue |
0.81% | 1.04% | 1.16% | 1.20% | |
Interest Coverage |
(2.60) | (3.21) | (6.76) | (4.39) | |
Operating CF/Net income |
0.10 | 0.02 | (0.05) | (0.23) | |
Depreciation/Fixed assets |
9.91 | 9.40 | 10.77 | 10.50 | |
Capex/Depreciation |
0.00 | 0.01 | (0.02) | (0.01) | |
Revenue per Share |
6.75 | 6.24 | 5.38 | 4.67 | |
Operating CF per Share |
(0.14) | (0.06) | 0.16 | 0.27 | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026